PITTSBURGH, June 26, 2018 /PRNewswire/ -- Earlier this month, medtech start-up Ebb Therapeutics was recognized with
MDEA, the premier awards program for the industry, recognizes significant achievements in medical product design and engineering that improve both the quality of healthcare delivery and its accessibility. Specific criteria include design and engineering innovation, user-friendly functionality and differentiated benefits for patients.
Worldwide entries are accepted across twelve product categories and are judged by a panel of impartial jurors – clinicians, engineers and designers. All products must have garnered FDA clearance.
Ebb Therapeutics' winning entry, Ebb Insomnia Therapy, was successfully designed to help the millions in the U.S. who suffer with insomnia. The patented, first-of-its-kind treatment works by precisely and consistently cooling the forehead, soothing a patient's mind and body, and allowing her/him to more quickly enter a deeper, more restorative sleep.
Don Spence, President & CEO, Ebb Therapeutics, said of the win: "The MDEA award is the most prominent and prestigious award in the medical device industry. It's an honor just to be recognized, but to win among this impressive, competitive field, is all the sweeter. I'm especially proud of two of my colleagues and fellow executive team members, Dr. Eric Nofzinger (Founder and Chief Medical Officer) and Jeff Schirm (VP, Engineering). Eric is a world-renowned, clinical sleep specialist who discovered this effective, safe and more natural way to help millions of sufferers. Jeff and his team turned Eric's vision into a reality, by engineering the product with uncompromising attention to detail for both efficacy and safety."
About Ebb TherapeuticsHeadquartered in Pittsburgh, the privately held company was founded in 2008 after the company's founder, Eric Nofzinger, M.D., performed pioneering brain imaging studies on insomnia patients at the University of Pittsburgh. His research resulted in the development of Ebb Insomnia Therapy, a clinically safe, medical grade device, with none of the side effects found in traditional treatments. Ebb Therapeutics was funded in part by a grant from the National Institutes of Health, as well as by private equity and venture capital firms, KKR, Arboretum Ventures, Versant Ventures and Partner Ventures.
To learn more, visit http://www.ebbsleep.com.
Or contact:Elise WilfingerChief Marketing Officer203-247-7420
View original content:http://www.prnewswire.com/news-releases/ebb-therapeutics-wins-silver-at-the-prestigious-mdea-awards-300672033.html
SOURCE Ebb Therapeutics
Subscribe to our Free Newsletters!
Tracheal or windpipe cancer is a rare cancer and its cause is unclear. The most common squamous ...
Tecovirimat can be used to treat smallpox disease in adult and pediatric patients who weigh at ...
Blount's disease is a developmental disorder in which the shinbone is affected, resulting in ...View All